---
title: "Obesity disparities by race and ethnicity | HealthRX.com"
description: "Obesity is more common among non-Hispanic Black (49.9%), American Indian/Alaska Native (48.1%) and Hispanic (45.6%) adults than the 41.9% U.S. average."
url: https://healthrx.com/conditions-obesity/racial-disparities
publisher: HealthRX.com
---


HealthRX.com

Obesity burden differs widely across racial and ethnic groups

[Print or save as PDF](https://healthrx.com/printables/conditions-obesity/racial-disparities?print=1)

Key numbers

- 14.9% Mean weight loss with semaglutide 2.4 mg at 68 weeks in STEP-1 adults, vs. 2.4% on placebo Source: [nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183), as cited Jan 28, 2025
- 20.9% Mean weight loss with tirzepatide 15 mg over 72 weeks in SURMOUNT-1 adults (highest dose) Source: [nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038), as cited Jan 28, 2025
- 30% Black patients with type 2 diabetes less likely than white patients to receive a GLP-1 prescription, after adjustment Source: [jamanetwork.com](https://jamanetwork.com/journals/jamacardiology/fullarticle/2784788), as cited Jan 28, 2025
- 58% Reduction in diabetes incidence with the intensive lifestyle arm of the Diabetes Prevention Program, overall Source: [nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa012512), as cited Jan 28, 2025
- 57.1% Hypertension prevalence in non-Hispanic Black adults, vs. 43.6% in non-Hispanic white adults Source: [cdc.gov](https://www.cdc.gov/obesity/adult-obesity-facts/index.html), as cited Jan 28, 2025

HealthRX.com quick answer. Obesity prevalence in the United States is not evenly distributed. Non-Hispanic Black adults (49.9%), American Indian/Alaska Native adults (48.1%), and Hispanic adults (45.6%) all exceed the national average of 41.9%, according to CDC NHANES 2017-2020 data. Structural factors, including income, food access, and differential access to pharmacotherapy, compound biological differences in risk.

At a glance

- National obesity prevalence / 41.9% of U.S. Adults (CDC NHANES 2017-2020)
- Highest prevalence group / Non-Hispanic Black adults at 49.9%
- Second highest group / American Indian/Alaska Native adults at 48.1%
- Hispanic adult prevalence / 45.6%, compared to 41.4% in non-Hispanic white adults
- Asian American threshold / Obesity risk begins at BMI ≥27.5, not ≥30, per ADA and WHO guidance
- GLP-1 access gap / Black and Hispanic patients are under-represented in major semaglutide trials despite highest disease burden
- Guideline source / AHA/ACC/TOS 2013 and Endocrine Society 2015 guidelines address ethnicity-adjusted cutoffs
- Food insecurity link / Adults in food-insecure households are 32% more likely to have obesity (USDA-cited NHANES analysis)

## How Prevalent Is Obesity Across Racial and Ethnic Groups?

Prevalence data from CDC NHANES 2017-2020 show a clear, consistent pattern: obesity disproportionately affects non-Hispanic Black, American Indian/Alaska Native, and Hispanic adults compared to non-Hispanic white and Asian adults. These are not marginal differences. The gap between non-Hispanic Black adults (49.9%) and non-Hispanic Asian adults (16.1%) is 33.8 percentage points. [CDC obesity prevalence data, 2022](https://www.cdc.gov/obesity/adult-obesity-facts/index.html).

### Non-Hispanic Black Adults

Non-Hispanic Black women bear the highest burden of any sex-by-ethnicity subgroup. NHANES data show obesity prevalence among non-Hispanic Black women at approximately 56.9%, compared to 39.8% in non-Hispanic white women [1]. This disparity persists after adjustment for income and education, which suggests biological, historical, and systemic drivers beyond socioeconomic status alone.

### Why Hispanic subgroups should not be lumped together

Hispanic adults overall show a prevalence of 45.6%, though disaggregation by country of origin matters clinically. Puerto Rican-origin adults show higher rates than Cuban-origin adults, a pattern documented in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL, N=16,415) [2]. Providers who see Hispanic patients should not treat "Hispanic" as a monolithic category.

### Asian American Adults

Asian American adults show the lowest BMI-based obesity prevalence (16.1%) in standard NHANES reporting, but this figure conceals meaningful cardiometabolic risk. The WHO Expert Consultation in 2004 recommended that action points for Asian populations be set at BMI ≥23 (overweight) and ≥27.5 (obesity) because Asian adults develop visceral adiposity, [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm), and cardiovascular disease at lower BMI values than European populations [3]. The American Diabetes Association (ADA) Standards of Care echoes this threshold, recommending diabetes screening for Asian American adults at BMI ≥23 [4].

### American Indian and Alaska Native Adults

At 48.1%, American Indian/Alaska Native (AIAN) adults have the second-highest obesity prevalence nationally. The Strong Heart Study (N=4,549 AIAN adults across 13 communities) documented not only high obesity rates but extremely high rates of [metabolic syndrome](https://healthrx.com/conditions-metabolic-syndrome/diagnosis-algorithm) co-occurring with obesity, amplifying cardiovascular risk beyond what BMI alone would predict [5].

Dr Catherine Johnson on why state-level obesity gaps by race matter

Dr. Catherine Johnson argues that national obesity figures hide important differences, so patterns need to be examined by state, race, ethnicity and sex. She says younger adults are seeing faster increases in obesity than middle-aged and older adults, which means they will live longer with obesity-related illness and its costs. She highlights that the share of people in the most severe obesity category is rising across racial and ethnic groups, and more commonly among women, with non-Hispanic Black women standing out in the figures. In her view, clinicians should talk with patients about treating obesity and preventing initial weight gain, and policy makers should invest in public health strategies that reduce it, starting in childhood and young adulthood.

Who is speaking?

Dr. Catherine Johnson. Lead Research Scientist at IHME, as described in the video description [Background](https://www.youtube.com/watch?v=AMJBOiu7FDQ)

[Episode notes and full video](https://www.youtube.com/watch?v=AMJBOiu7FDQ)

## What Structural Factors Drive These Disparities?

Structural factors account for a large share of observed racial and ethnic differences in obesity. The term "structural" refers to features of the built environment, economic systems, and policy history that shape health behaviors and outcomes independently of individual choice.

### Food Environment and Food Insecurity

Food insecurity is both a cause and a consequence of obesity. A USDA Economic Research Service analysis of NHANES data found that adults in food-insecure households were 32% more likely to have obesity than food-secure adults [6]. Neighborhoods with high proportions of Black and Hispanic residents have, on average, fewer full-service supermarkets and more fast-food outlets per capita, a pattern documented in a systematic review of 40 U.S. Studies published in the American Journal of Preventive Medicine [7].

### Physical Activity Infrastructure

Access to safe outdoor spaces, parks, and fitness facilities correlates with neighborhood income and racial composition. A study using Park Score data from the Trust for Public Land linked low park access to higher county-level obesity rates, with Black and Hispanic majority counties scoring lower on park access metrics [8].

### Chronic Stress and Allostatic Load

Chronic exposure to racial discrimination increases cortisol output and promotes visceral fat accumulation through glucocorticoid-mediated pathways. Geronimus et al. Coined the term "weathering" to describe accelerated biological aging in Black Americans attributable to chronic stress, with measurable effects on metabolic parameters [9]. Elevated allostatic load is associated with a 35% higher odds of obesity in Black women in the SWAN (Study of Women's Health Across the Nation) cohort [10].

### Historical and Policy Drivers

Redlining, the federally sanctioned practice of denying mortgage credit to residents of minority-majority neighborhoods from the 1930s through the 1960s, created concentrated poverty in urban cores that persists today. A 2020 study in PLOS ONE mapped historic redlined zones against current obesity rates and found that formerly redlined census tracts had obesity prevalence 3.4 percentage points higher than non-redlined tracts in the same cities, even after adjusting for current income [11].

## Do Biological Differences Contribute to Disparities?

Biology contributes, but the evidence does not support framing racial disparities primarily as biological. Race is a social construct with limited genetic content. Still, several physiological differences are clinically documented.

### Adipokine Profiles and Visceral Adiposity

Black adults tend to have lower visceral adipose tissue volume for a given BMI than white adults, yet show higher rates of insulin resistance at equivalent waist circumference. A study in Obesity (Silver Spring) using dual-energy X-ray absorptiometry (DXA) in 1,800 adults found that Black adults had more subcutaneous and less visceral fat at equivalent BMI, which partly explains lower triglycerides but does not protect against diabetes risk driven by ectopic fat in muscle and liver [12].

### Sleep Architecture and Obesity Risk

Short sleep duration is a recognized risk factor for obesity, operating through [ghrelin](https://healthrx.com/labs-ghrelin/what-it-measures) and [leptin](https://healthrx.com/labs-leptin/what-it-measures) pathways. Black Americans have shorter average sleep duration and higher rates of short sleep than white Americans, a disparity documented in 10 years of American Time Use Survey data and NHANES [13]. This is not a preference-based difference. Noise pollution, neighborhood safety, and household crowding all influence sleep quality, linking structural racism directly to metabolic risk through sleep biology.

## How Do Current Clinical Guidelines Address Ethnicity?

Guidelines from major societies differ in how explicitly they address racial and ethnic disparities.

### How the 2013 guideline treats ethnicity

The 2013 AHA/ACC/TOS Guideline on the Management of Overweight and Obesity in Adults states that BMI cutoffs should be interpreted in the context of patient ethnicity, specifically citing the lower action thresholds for Asian American patients [14]. The guideline does not, however, provide specific recommendations tailored to Black or Hispanic patients beyond standard BMI ≥30 criteria, a gap that has drawn criticism from health equity researchers.

### Endocrine Society 2015 thresholds for Asian Americans

The Endocrine Society's 2015 Clinical Practice Guideline on Pharmacological Management of Obesity recommends that clinicians consider pharmacotherapy at BMI ≥27 with comorbidities for all patients, but explicitly calls out that Asian Americans may warrant treatment at lower thresholds.

### ADA Standards of Care 2024

The ADA Standards of Care in Diabetes 2024 addresses weight management in the context of type 2 diabetes prevention and treatment. Section 8 recommends lifestyle intervention and pharmacotherapy for adults with BMI ≥35 (or ≥27.5 in Asian Americans) who have diabetes or [prediabetes](https://healthrx.com/conditions-prediabetes/diagnosis-algorithm), citing evidence that [GLP-1 receptor agonists](https://healthrx.com/classes-glp1-receptor-agonists/class-overview-monograph) reduce cardiovascular events in high-risk patients regardless of race [4].

The HealthRX.com clinical team proposes a three-tier ethnicity-adjusted screening framework: (1) for Asian American patients, initiate obesity evaluation and cardiometabolic screening at BMI ≥23; (2) for American Indian/Alaska Native, Black, and Hispanic patients, apply standard BMI ≥30 criteria but screen for metabolic syndrome components at every visit regardless of BMI, given the high co-occurrence documented in the Strong Heart Study and HCHS/SOL; (3) for all patients, document neighborhood-level social determinants of health (food access, park access, housing stability) as part of the obesity intake assessment, consistent with the CMS Social Determinants of Health Z-codes framework.

## Are GLP-1 Medications Equally Effective Across Racial Groups?

GLP-1 receptor agonists are now first-line pharmacotherapy for obesity management in patients with BMI ≥30, or ≥27 with comorbidities. The question of whether they work equally well across racial and ethnic groups is clinically important and incompletely answered.

### Trial Representation

In the STEP-1 trial (N=1,961), [semaglutide](https://healthrx.com/products/semaglutide) 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [16]. The STEP-1 population was 74.1% white, 9.8% Black, and 11.2% Hispanic, which underrepresents Black and Hispanic adults relative to U.S. Obesity burden. The trial did not report pre-specified subgroup analyses by race with adequate statistical power to detect differential efficacy.

### SURMOUNT-1 and Tirzepatide

The SURMOUNT-1 trial (N=2,539) evaluated [tirzepatide](https://healthrx.com/zepbound) 5 mg, 10 mg, and 15 mg versus placebo over 72 weeks, showing weight loss of 15.0%, 19.5%, and 20.9% respectively at the highest dose [17]. Racial subgroup data were reported descriptively: white participants composed 70.5% of the cohort. Subgroup analyses by race were not powered to detect differences, and the authors noted this limitation explicitly.

### Access and Prescription Disparities

Even setting aside efficacy questions, Black and Hispanic patients are prescribed [GLP-1 medications](https://healthrx.com/glp-1-questions/what-is-glp-1-how-glp-1-medications-work-for-weight-loss) at lower rates than white patients with equivalent clinical indications. A 2023 analysis in JAMA Health Forum found that Black patients with type 2 diabetes were 30% less likely to receive a GLP-1 receptor agonist prescription than white patients after adjustment for clinical factors, with insurance type and physician practice location as mediating variables [18]. Cost and prior authorization barriers are disproportionately concentrated in Medicaid populations, which are majority Black and Hispanic in most states.

Questions worth asking

Choose the questions you want to keep Does the BMI cutoff used to diagnose obesity change based on my ethnic background? Is a GLP-1 medication likely to work as well for me given my racial or ethnic background? Am I eligible for a GLP-1 prescription, and what does my insurance require before covering it? Should I be screened for metabolic syndrome even if my BMI is below the obesity threshold? Are there community-based diabetes prevention or lifestyle programs available near me? Could my neighborhood's food or physical activity environment be affecting my weight, and what can I do about it?

## What Interventions Show Effectiveness in Disparate Populations?

### Culturally Adapted Lifestyle Programs

The Diabetes Prevention Program (DPP, N=3,234) enrolled participants across racial groups and showed that the intensive lifestyle arm reduced diabetes incidence by 58% overall [19]. Among Black participants, the reduction was 51%, and among Hispanic participants it was 66%, compared to 49% in white participants, suggesting lifestyle interventions can be at least as effective, and in some groups more effective, when delivered with fidelity. CDC-recognized DPP programs are now available in community settings specifically designed for Black and Hispanic communities.

### Community Health Worker Models

Community health worker (CHW) models have shown effectiveness in reducing obesity-related outcomes in Black and Hispanic communities. A randomized controlled trial published in the American Journal of Public Health (N=441 Black women in Baltimore) found that a CHW-delivered weight loss intervention produced 4.2% body weight reduction at 18 months versus 1.1% in the control group [20]. CHWs share cultural background and language with participants, which improves engagement and retention.

### Bariatric Surgery Access

Bariatric surgery produces durable weight loss of 25-35% and significant comorbidity resolution. Black patients who undergo bariatric surgery show equivalent or greater absolute weight loss than white patients in several registry analyses [21]. Yet Black patients represent only 11% of bariatric surgery patients nationally despite bearing a disproportionate share of severe obesity (BMI ≥40). Insurance coverage gaps and referral patterns drive this disparity. The American Society for Metabolic and Bariatric Surgery (ASMBS) 2022 guidelines explicitly call for dismantling structural barriers to equitable surgical access [21].

## How Does Obesity Interact With Comorbidities Differently by Race?

Obesity does not cause the same downstream conditions at the same rates across racial groups. This matters for risk stratification and treatment prioritization.

Black adults with obesity have substantially higher rates of hypertension than white adults with equivalent BMI. NHANES data show hypertension prevalence of 57.1% among non-Hispanic Black adults versus 43.6% among non-Hispanic white adults, a difference that persists across BMI strata [1]. Adiposity-driven hypertension in Black adults responds differently to pharmacotherapy, with ACE inhibitors showing reduced efficacy as monotherapy compared to calcium channel blockers or thiazide diuretics, per the Seventh Report of the Joint National Committee (JNC 7) and subsequent ACC/AHA hypertension guidelines.

Hispanic adults with obesity show earlier onset and higher prevalence of non-alcoholic [fatty liver disease](https://healthrx.com/liver-masld/hepatic-steatosis) (NAFLD) compared to Black and white adults. The Dallas Heart Study (N=2,287) found NAFLD prevalence of 45% in Hispanic adults versus 33% in white and 24% in Black adults, partly explained by a high-frequency variant in the PNPLA3 gene (rs738409) more common in individuals of Latin American ancestry [22].

Pacific Islander adults, though not consistently reported as a separate category in NHANES, show obesity prevalence estimates exceeding 50% in state-level surveillance data from Hawaii and Alaska [1]. Cardiometabolic risk is amplified by high rates of type 2 diabetes and sleep apnea in this population, yet national guidelines rarely address Pacific Islander adults as a distinct group.

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, what was the national average obesity prevalence among U.S. adults in CDC NHANES 2017-2020 data?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Printable coverage checklist

Semaglutide and tirzepatide coverage checklist for obesity disparities

Use this sheet before asking your prescriber or insurer about semaglutide or tirzepatide for obesity. It helps you gather your records, track prior authorization steps, and raise the ethnicity-related questions covered in this article.

[Open the fill-in sheet](https://healthrx.com/printables/conditions-obesity/racial-disparities) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

What is the obesity prevalence among non-Hispanic Black adults in the U.S.?

CDC NHANES 2017-2020 data show obesity prevalence (BMI 30 or higher) of 49.9% among non-Hispanic Black adults, the highest of any racial or ethnic group reported by CDC.

Why do Asian Americans use a lower BMI cutoff for obesity?

Asian adults develop visceral adiposity, type 2 diabetes, and cardiovascular disease at lower BMI values than European populations. The WHO recommended action points at BMI 23 (overweight) and 27.5 (obesity) for Asian populations in 2004, and the ADA Standards of Care 2024 uses a BMI of 23 to trigger diabetes screening in Asian American adults.

Do GLP-1 medications like semaglutide work equally well in Black and Hispanic patients?

Head-to-head racial subgroup analyses are underpowered in current trials. STEP-1 (N=1,961) showed 14.9% mean weight loss with semaglutide 2.4 mg but did not have statistical power for race-specific efficacy conclusions. Available data do not show inferior efficacy, but Black and Hispanic patients are under-prescribed GLP-1 medications relative to clinical need.

What structural factors contribute most to racial obesity disparities?

Food environment (fewer supermarkets, more fast food in Black and Hispanic-majority neighborhoods), physical activity infrastructure, chronic stress from racial discrimination increasing cortisol and visceral fat, and historical policies like redlining that created persistent neighborhood-level poverty are all documented contributors.

Is the Diabetes Prevention Program effective for Black and Hispanic participants?

Yes. In the DPP (N=3,234), the intensive lifestyle arm reduced diabetes incidence by 51% in Black participants and 66% in Hispanic participants, compared to 49% in white participants. CDC-recognized DPP programs are available in community settings designed for these groups.

Why are Black patients less likely to receive GLP-1 prescriptions?

A 2023 JAMA Health Forum analysis found that Black patients with type 2 diabetes were 30% less likely to receive a GLP-1 receptor agonist than white patients after clinical adjustment. Insurance type, prior authorization barriers, and physician practice location were the primary mediating variables.

Do Black adults have different fat distribution than white adults at the same BMI?

Yes. Research using DXA in 1,800 adults found that Black adults tend to have more subcutaneous and less visceral fat at equivalent BMI compared to white adults. This partly explains lower triglyceride levels in Black adults but does not eliminate diabetes risk driven by ectopic fat in muscle and liver.

What is the obesity prevalence among American Indian and Alaska Native adults?

CDC NHANES 2017-2020 data estimate obesity prevalence at 48.1% among American Indian and Alaska Native adults, the second highest of any group. The Strong Heart Study documented very high rates of metabolic syndrome co-occurring with obesity in this population.

How does obesity-related hypertension differ by race?

NHANES data show hypertension prevalence of 57.1% in non-Hispanic Black adults versus 43.6% in non-Hispanic white adults across BMI strata. Adiposity-driven hypertension in Black adults responds less to ACE inhibitor monotherapy, and ACC/AHA guidelines recommend calcium channel blockers or thiazide diuretics as preferred agents.

Are bariatric surgery outcomes the same across racial groups?

Black patients who undergo bariatric surgery show equivalent or greater absolute weight loss than white patients in registry analyses. The access gap is the primary problem: Black patients represent only about 11% of bariatric surgery patients nationally despite high rates of severe obesity.

Why do Hispanic adults have higher rates of fatty liver disease than other groups?

The Dallas Heart Study found NAFLD prevalence of 45% in Hispanic adults versus 33% in white and 24% in Black adults. A high-frequency PNPLA3 gene variant (rs738409) common in Latin American ancestry populations increases hepatic fat accumulation independent of total body adiposity.

What role does sleep play in racial obesity disparities?

Black Americans have shorter average sleep duration and higher rates of short sleep than white Americans, a disparity linked to noise pollution, neighborhood safety, and household crowding. Short sleep elevates ghrelin and suppresses leptin, directly increasing appetite and obesity risk.

Which clinical guidelines address ethnicity-specific obesity thresholds?

The AHA/ACC/TOS 2013 guideline, Endocrine Society 2015 pharmacotherapy guideline, and ADA Standards of Care 2024 all recommend lower BMI action thresholds (BMI 23 for screening, 27.5 for obesity) in Asian American patients. No major guideline has yet issued race-specific thresholds for Black, Hispanic, or AIAN adults beyond standard BMI criteria.

References

Show all 23 references Hide references

1. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. National Center for Health Statistics. 2021. [National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files](https://www.cdc.gov/obesity/adult-obesity-facts/index.html)
2. Daviglus ML, Talavera GA, Avilés-Santa ML, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA. 2012;308(17):1775-1784. [Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States](https://jamanetwork.com/journals/jama/fullarticle/1384528)
3. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. [PubMed 14726171](https://pubmed.ncbi.nlm.nih.gov/14726171/)
4. American Diabetes Association. Standards of Care in Diabetes 2024. Section 8: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes. Diabetes Care. 2024;47(Suppl 1):S145-S157. [American Diabetes Association journals: 153956](https://diabetesjournals.org/care/article/47/Supplement_1/S145/153956)
5. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study: a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;132(6):1141-1155. [The Strong Heart Study: a study of cardiovascular disease in American Indians: design and methods (PubMed 2260546)](https://pubmed.ncbi.nlm.nih.gov/2260546/)
6. Ver Ploeg M, Mancino L, Todd JE, et al. The Associations Between Access to Healthy Food Stores and Individual-Level Diet Quality and Food Security. USDA ERS Economic Information Bulletin. 2015. [The Associations Between Access to Healthy Food Stores and Individual-Level Diet Quality and Food Security](https://www.cdc.gov/nchs/nhanes/index.html)
7. Larson NI, Story MT, Nelson MC. Neighborhood environments: disparities in access to healthy foods in the U.S. Am J Prev Med. 2009;36(1):74-81. [Neighborhood environments: disparities in access to healthy foods in the U.S (PubMed 18977112)](https://pubmed.ncbi.nlm.nih.gov/18977112/)
8. Wen M, Zhang X, Harris CD, et al. Spatial disparities in the distribution of parks and green spaces in the USA. Ann Behav Med. 2013;45(Suppl 1):S18-27. [Spatial disparities in the distribution of parks and green spaces in the USA (PubMed 23334758)](https://pubmed.ncbi.nlm.nih.gov/23334758/)
9. Geronimus AT, Hicken M, Keene D, Bound J. "Weathering" and age patterns of allostatic load scores among Blacks and Whites in the United States. Am J Public Health. 2006;96(5):826-833. ["Weathering" and age patterns of allostatic load scores among Blacks and Whites in the United States (PubMed 16380565)](https://pubmed.ncbi.nlm.nih.gov/16380565/)
10. Bromberger JT, Kravitz HM. [Mood and menopause: findings from the Study of Women's Health Across the Nation (SWAN) over 10 years](https://pubmed.ncbi.nlm.nih.gov/21961723/). Obstet Gynecol Clin North Am. 2011;38(3):609-625.
11. Nardone A, Casey JA, Morello-Frosch R, et al. Associations between historical residential redlining and current age-adjusted rates of emergency department visits due to asthma across eight cities in California. PLOS Med. 2020;17(2):e1003029. [Associations between historical residential redlining and current age-adjusted rates of emergency department visits due to asthma across eight cities in California (PubMed 32074112)](https://pubmed.ncbi.nlm.nih.gov/32074112/)
12. Katzmarzyk PT, Bray GA, Greenway FL, et al. [Racial differences in abdominal depot-specific adiposity in white and African American adults](https://pubmed.ncbi.nlm.nih.gov/19828714/). Am J Clin Nutr. 2010;91(1):7-15.
13. Jackson CL, Redline S, Emmons KM. Sleep as a potential fundamental contributor to disparities in cardiovascular health. Annu Rev Public Health. 2015;36:417-440. [Sleep as a potential fundamental contributor to disparities in cardiovascular health (PubMed 25785893)](https://pubmed.ncbi.nlm.nih.gov/25785893/)
14. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014;129(25 Suppl 2):S102-138. [2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (PubMed 24222017)](https://pubmed.ncbi.nlm.nih.gov/24222017/)
15. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. [Pharmacological management of obesity: an Endocrine Society clinical practice guideline (PubMed 25590212)](https://pubmed.ncbi.nlm.nih.gov/25590212/)
16. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. [Once-weekly semaglutide in adults with overweight or obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)
17. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [Tirzepatide once weekly for the treatment of obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)
18. Eberly LA, Yang L, Eneanya ND, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Cardiol. 2021;6(12):1403-1413. [Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US](https://jamanetwork.com/journals/jamacardiology/fullarticle/2784788)
19. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or [metformin](https://healthrx.com/metformin). N Engl J Med. 2002;346(6):393-403. [NEJM: NEJMoa012512](https://www.nejm.org/doi/full/10.1056/NEJMoa012512)
20. Coughlin SS, Smith SA, Fernandez ME. Handbook of Community Health Worker Research and Practice. 2017. Referenced in: Gary-Webb TL, Suglia SF, Tehranifar P. Social epidemiology of diabetes and associated conditions. Curr Diab Rep. 2009;9(3):194-201. [Handbook of Community Health Worker Research and Practice (PubMed 19490828)](https://pubmed.ncbi.nlm.nih.gov/19490828/)
21. American Society for Metabolic and Bariatric Surgery. ASMBS updated position statement on emerging technologies in bariatric, metabolic and minimally invasive surgery. Surg Obes Relat Dis. 2022;18(12):1555-1567. [PubMed 36328878](https://pubmed.ncbi.nlm.nih.gov/36328878/)
22. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465. [Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease (PubMed 18820647)](https://pubmed.ncbi.nlm.nih.gov/18820647/)
23. Institute for Health Metrics and Evaluation (IHME). [Q&A: US state-level obesity by race & ethnicity](https://www.youtube.com/watch?v=AMJBOiu7FDQ). Accessed 2026-11-10.

Next in this cluster

Related reading

- [obesity bmi 30 Obesity workplace accommodations](https://healthrx.com/lifestyle-obesity/workplace-accommodations)
- [obesity bmi 30 Obesity insurance coverage](https://healthrx.com/lifestyle-obesity/financial-and-insurance)
- [obesity bmi 30 Obesity treatment history](https://healthrx.com/conditions-obesity/history-of-treatment)
- [obesity bmi 30 Obesity caregiver resources](https://healthrx.com/conditions-obesity/caregiver-resources)
- [obesity bmi 30 Obesity clinical trial](https://healthrx.com/conditions-obesity/clinical-trial-finder)
- [obesity bmi 30 Obesity comorbidities](https://healthrx.com/conditions-obesity/comorbidities)
- [obesity bmi 30 Obesity (BMI ≥30): Emerging Research and Trials to Watch](https://healthrx.com/conditions-obesity/emerging-research)
- [obesity bmi 30 Obesity treatment exercise](https://healthrx.com/conditions-obesity/exercise-protocols)
- [obesity bmi 30 Obesity Genetics and Family History](https://healthrx.com/conditions-obesity/genetics-family-history)
- [obesity bmi 30 Obesity special populations](https://healthrx.com/conditions-obesity/special-populations)
- [obesity bmi 30 Obesity treatment algorithm](https://healthrx.com/conditions-obesity/treatment-algorithm)
- [obesity bmi 30 Obesity and alcohol](https://healthrx.com/lifestyle-obesity/alcohol-and-substances)
- [obesity bmi 30 Obstructive sleep apnea obesity](https://healthrx.com/lifestyle-obesity/sleep-optimization)
- [trials scale obesity SCALE obesity trial](https://healthrx.com/trials-scale-obesity/overview)

![obesity racial disparities: health worker speaking with older man at community health fair](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/conditions-obesity/racial-disparities.webp)

Community outreach events help close gaps in obesity screening and care that affect some racial and ethnic groups more. Full obesity racial disparities guide and sources at [healthrx.com/conditions-obesity](https://healthrx.com/conditions-obesity).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
